Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Budget Proposal: It’s The User Fees’ Agency Now

Executive Summary

User fees, not appropriations, will make up the bulk of FDA’s human drug spending if President Obama’s FY 2014 budget comes to pass, a trend fueled by new user fee programs and cuts to taxpayer funding.

You may also be interested in...



FDA Funding Gets Boost In Cures Bill, But Is Industry Pleased?

Several trade associations offer little praise for additional funding as 21st Century Cures bill moves to House floor.

Cost Of FDA Reforms Is Big Challenge For ‘Cures’ Legislation

Drug industry warns that unfunded mandates in the 21st Century Cures discussion document could impact FDA’s ability to focus on drug reviews; Energy and Commerce legislators are working to get appropriators on board.

Budget Reductions Target FDA Field Operations

President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.

Related Content

Topics

UsernamePublicRestriction

Register

PS055267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel